[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611921":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":63,"centralContacts":67,"locations":72,"responsibleParty":469,"collaborators":62,"id":471,"slug":472,"hasResults":473,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":62,"eligibilityCriteria":477,"healthyVolunteers":473,"sex":478,"minAge":479,"maxAge":62,"enrollmentInfo":480,"targetDuration":62,"studyType":483,"phases":484,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":75,"whyStopped":62,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":502},{"fullName":5,"class":6},"CatalYm GmbH","INDUSTRY",[8,16,21,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Visugromab (RDE) + Nivolumab (360 mg) + Docetaxel (75 mg\u002Fm2), intravenous (IV) on Day 1 of every 21-day cycle every 3 weeks (Q3W)",[13,14,15],"Biological: Visugromab RDE (recommended dose for expansion)","Biological: Nivolumab","Drug: Docetaxel",{"label":17,"type":10,"description":18,"interventionNames":19},"Arm B","Visugromab (6mg\u002Fkg) + Nivolumab (360 mg) + Docetaxel (75 mg\u002Fm2), intravenous (IV) on Day 1 of every 21-day cycle every 3 weeks (Q3W)",[20,14,15],"Biological: Visugromab 6mg\u002Fkg",{"label":22,"type":10,"description":23,"interventionNames":24},"Arm C","Visugromab (RDE) + Nivolumab (360 mg) + Placebo (Saline) intravenous (IV) on Day 1 of every 21-day cycle every 3 weeks (Q3W)",[13,14],{"label":26,"type":27,"description":28,"interventionNames":29},"Arm D","ACTIVE_COMPARATOR","Double Placebo (Saline) + Docetaxel (75 mg\u002Fm2), intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)",[30,15],"Other: Placebo Saline Infusion",[32,39,44,50,57],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"BIOLOGICAL","Visugromab RDE (recommended dose for expansion)","Participants receive Visugromab (RDE) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)",[9,22],[38],"CTL-002",{"type":33,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Visugromab 6mg\u002Fkg","Participants receive Visugromab (6mg\u002Fkg) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)",[17],[38],{"type":33,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Nivolumab","Participants receive Nivolumab 360mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)",[9,17,22],[49],"OPDIVO®",{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"OTHER","Placebo Saline Infusion","Participants receive Saline intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)",[26],[56],"0.9% NaCl",{"type":58,"name":59,"description":60,"armGroupLabels":61,"otherNames":62},"DRUG","Docetaxel","Participants receive Docetaxel 75 mg\u002Fm2 intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)",[9,17,26],null,[64],{"name":65,"affiliation":5,"role":66},"Lena Lemke, MD","STUDY_DIRECTOR",[68],{"name":65,"role":69,"phone":70,"phoneExt":62,"email":71},"CONTACT","+49 89 200066440","regulatory-004@catalym.com",[73,92,107,121,136,157,172,187,201,218,235,250,266,280,301,320,339,356,370,385,400,414,425,439,455],{"facility":74,"status":75,"city":76,"state":77,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":87},"University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)","RECRUITING","Birmingham","Alabama","35294-3300","United States","US",{"type":82,"coordinates":83},"Point",[84,85],-86.80249,33.52066,{"lat":85,"lon":84},[88],{"name":89,"role":69,"phone":90,"phoneExt":62,"email":91},"Leigh McManus, RN, MSHQS, CCRP","205-934-4173","lmcmanus@uabmc.edu",{"facility":93,"status":75,"city":94,"state":95,"zip":96,"country":79,"countryCode":80,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"USC Norris Comprehensive Cancer Center","Los Angeles","California","90033",{"type":82,"coordinates":98},[99,100],-118.24368,34.05223,{"lat":100,"lon":99},[103],{"name":104,"role":69,"phone":105,"phoneExt":62,"email":106},"Sandy Tran","323-865-3935","Sandy.Tran@med.usc.edu",{"facility":108,"status":75,"city":109,"state":109,"zip":110,"country":79,"countryCode":80,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"NYU Longone Health","New York","10016",{"type":82,"coordinates":112},[113,114],-74.00597,40.71427,{"lat":114,"lon":113},[117],{"name":118,"role":69,"phone":119,"phoneExt":62,"email":120},"Rajwanth Veluswamy, Dr","212-731-5662","rajwanth.veluswamy@nyulangone.org",{"facility":122,"status":75,"city":123,"state":124,"zip":125,"country":79,"countryCode":80,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Duke University Medical Center","Durham","North Carolina","27710",{"type":82,"coordinates":127},[128,129],-78.89862,35.99403,{"lat":129,"lon":128},[132],{"name":133,"role":69,"phone":134,"phoneExt":62,"email":135},"Alicia Wilkerson","919-681-4768","Alicia.wilkerson@duke.edu",{"facility":137,"status":75,"city":138,"state":139,"zip":140,"country":141,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Hospital Esslingen GmbH","Esslingen am Neckar","Baden-Wurttemberg","73730","Germany","DE",{"type":82,"coordinates":144},[145,146],9.30473,48.73961,{"lat":146,"lon":145},[149,153],{"name":150,"role":69,"phone":151,"phoneExt":62,"email":152},"Martin Faehling, Dr","+49711310382411","m.faehling@klinikum-esslingen.de",{"name":154,"role":69,"phone":155,"phoneExt":62,"email":156},"Annika Landmesser","+49711310386510","a.landmesser@klinikum-esslingen.de",{"facility":158,"status":75,"city":159,"state":160,"zip":161,"country":141,"countryCode":142,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"University Hospital Wuerzburg, Clinic and Polyclinic II for Gastroenterology, Hematology, Internal Oncology, Stem Cell Therapies, Hepatology, Infectiology, Psychosomatics and Rheumatology\u002F Clinical Immunology","Würzburg","Bavaria","97080",{"type":82,"coordinates":163},[164,165],9.95121,49.79391,{"lat":165,"lon":164},[168],{"name":169,"role":69,"phone":170,"phoneExt":62,"email":171},"Maria- Elisabeth Goebeler, Dr","+49 93120140959","goebeler_m@ukw.de",{"facility":173,"status":75,"city":174,"state":175,"zip":176,"country":141,"countryCode":142,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology\u002FOncology, Palliative Medicine Johannesstift","Bielefeld","North Rhine-Westphalia","33611",{"type":82,"coordinates":178},[179,180],8.53333,52.03333,{"lat":180,"lon":179},[183],{"name":184,"role":69,"phone":185,"phoneExt":62,"email":186},"Florian Weissinger, Prof.","+49 (521) 77275750","florian.weissinger@evkb.de",{"facility":188,"status":75,"city":189,"state":175,"zip":190,"country":141,"countryCode":142,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Clinics Essen-Mitte","Essen","45136",{"type":82,"coordinates":192},[193,194],7.01228,51.45657,{"lat":194,"lon":193},[197],{"name":198,"role":69,"phone":199,"phoneExt":62,"email":200},"Konstantinos Ferentinos, Dr","+49 (201) 174-24061","K.Ferentinos@kem-med.com",{"facility":202,"status":75,"city":203,"state":175,"zip":204,"country":141,"countryCode":142,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Foundation Bethanien Moers","Moers","47441",{"type":82,"coordinates":206},[207,208],6.6326,51.45342,{"lat":208,"lon":207},[211,215],{"name":212,"role":69,"phone":213,"phoneExt":62,"email":214},"Kato Kambartel, Dr","+49 2841 200 2297","kambartel@bethanienmoers.de",{"name":216,"role":69,"phone":213,"phoneExt":62,"email":217},"Sylvia Quabeck, Dr","Sylvia.Quabeck@bethanienmoers.de",{"facility":219,"status":75,"city":220,"state":221,"zip":222,"country":223,"countryCode":224,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Institute of Romagna for Cancer Research \"Dino Amadori\" - IRCCS IRST","Forlì","Emilia-Romagna","47014","Italy","IT",{"type":82,"coordinates":226},[227,228],12.04144,44.22177,{"lat":228,"lon":227},[231],{"name":232,"role":69,"phone":233,"phoneExt":62,"email":234},"Oriana Nanni, Dr","+39 0543739100","oriana.nanni@irst.emr.it",{"facility":236,"status":75,"city":237,"state":238,"zip":239,"country":223,"countryCode":224,"cosmosGeoPoint":240,"geoPoint":244,"contacts":245},"Oncology Reference Center","Aviano","Friuli Venezia Giulia","33081",{"type":82,"coordinates":241},[242,243],12.59472,46.07056,{"lat":243,"lon":242},[246],{"name":247,"role":69,"phone":248,"phoneExt":62,"email":249},"Brigida Stanzione, Dr","+39 0434659314","brigida.stanzione@cro.it",{"facility":251,"status":75,"city":252,"state":253,"zip":254,"country":223,"countryCode":224,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"National Cancer Institute Regina Elena, IRCCS","Rome","Lazio","00144",{"type":82,"coordinates":256},[257,258],12.51133,41.89193,{"lat":258,"lon":257},[261],{"name":262,"role":69,"phone":263,"phoneExt":264,"email":265},"Gabriele Minuti, Dr","+39 06 5266 2205","06","gabriele.minuti@ifo.it",{"facility":267,"status":75,"city":268,"state":62,"zip":269,"country":223,"countryCode":224,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"Local Health Unit of Romagna - Santa Maria delle Croci Hospital of Ravenna, Onco-Hematology Department","Ravenna","48121",{"type":82,"coordinates":271},[272,273],12.20121,44.41344,{"lat":273,"lon":272},[276],{"name":277,"role":69,"phone":278,"phoneExt":62,"email":279},"Manolo D'Arcangelo, Dr","+39 0544286223","manolo.darcangelo@auslromagna.it",{"facility":281,"status":75,"city":282,"state":283,"zip":284,"country":285,"countryCode":286,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"Sf. Nectarie Oncology Center","Craiova","Dolj","200542","Romania","RO",{"type":82,"coordinates":288},[289,290],23.8,44.31667,{"lat":290,"lon":289},[293,297],{"name":294,"role":69,"phone":295,"phoneExt":62,"email":296},"Michael Schenker, Dr","+40 727 774 974","mike_schenker@yahoo.com",{"name":298,"role":69,"phone":299,"phoneExt":62,"email":300},"Augustin Georghe","+40 723 557 512","gusti.gheorghe@yahoo.com",{"facility":302,"status":75,"city":303,"state":304,"zip":305,"country":285,"countryCode":286,"cosmosGeoPoint":306,"geoPoint":310,"contacts":311},"Clinica Polisano S.R.L","Sibiu","Sibiu County","55023",{"type":82,"coordinates":307},[308,309],24.15,45.8,{"lat":309,"lon":308},[312,316],{"name":313,"role":69,"phone":314,"phoneExt":62,"email":315},"Victor Nimirceag, Dr","+40 (74) 103 3998","Dr.Nimirceag@gmail.com",{"name":317,"role":69,"phone":318,"phoneExt":62,"email":319},"Nicoleta Dalbea","+40 (752) 888 592","nicoleta.dalbea@medlife.ro",{"facility":321,"status":75,"city":322,"state":323,"zip":324,"country":285,"countryCode":286,"cosmosGeoPoint":325,"geoPoint":329,"contacts":330},"SC Oncomed SRL","Timișoara","Timiș County","300239",{"type":82,"coordinates":326},[327,328],21.22571,45.75372,{"lat":328,"lon":327},[331,335],{"name":332,"role":69,"phone":333,"phoneExt":62,"email":334},"Daniela Sirbu, Dr","+40 (744) 571 617","desirbu@yahoo.com",{"name":336,"role":69,"phone":337,"phoneExt":62,"email":338},"Georgeta Negret, Pharm","+40 (728) 963 979","gnegret28@gmail.com",{"facility":340,"status":75,"city":341,"state":342,"zip":343,"country":344,"countryCode":345,"cosmosGeoPoint":346,"geoPoint":350,"contacts":351},"University Hospital of Jaen","Jaén","Andalusia","23007","Spain","ES",{"type":82,"coordinates":347},[348,349],-3.79028,37.76922,{"lat":349,"lon":348},[352],{"name":353,"role":69,"phone":354,"phoneExt":62,"email":355},"Jose Lopez Lopez, Dr","+34 (95) 322 0306","Jall92hs@gmail.com",{"facility":357,"status":75,"city":358,"state":342,"zip":359,"country":344,"countryCode":345,"cosmosGeoPoint":360,"geoPoint":364,"contacts":365},"Regional University Hospital of Malaga","Málaga","29010",{"type":82,"coordinates":361},[362,363],-4.42034,36.72016,{"lat":363,"lon":362},[366],{"name":367,"role":69,"phone":368,"phoneExt":62,"email":369},"Manuel Cobo Dols, Dr","+34 (95) 130 8130","mangel.cobo.sspa@juntadeandalucia.es",{"facility":371,"status":75,"city":372,"state":373,"zip":374,"country":344,"countryCode":345,"cosmosGeoPoint":375,"geoPoint":379,"contacts":380},"University Hospital Complex of Santiago (CHUS)","Santiago de Compostela","Galicia","15706",{"type":82,"coordinates":376},[377,378],-8.54569,42.88052,{"lat":378,"lon":377},[381],{"name":382,"role":69,"phone":383,"phoneExt":62,"email":384},"Estiban Mendez Barrio","+34 981 955 923","estiban.mendez.barrio@sergas.es",{"facility":386,"status":75,"city":387,"state":388,"zip":389,"country":344,"countryCode":345,"cosmosGeoPoint":390,"geoPoint":394,"contacts":395},"START- Rioja","Logroño","La Rioja","26006",{"type":82,"coordinates":391},[392,393],-2.45115,42.46615,{"lat":393,"lon":392},[396],{"name":397,"role":69,"phone":398,"phoneExt":62,"email":399},"Carme Bistuer Rovira","+34941278760","carme.bistuer@startresearch.com",{"facility":401,"status":75,"city":402,"state":402,"zip":403,"country":344,"countryCode":345,"cosmosGeoPoint":404,"geoPoint":408,"contacts":409},"University Hospital 12 de Octubre","Madrid","28041",{"type":82,"coordinates":405},[406,407],-3.70256,40.4165,{"lat":407,"lon":406},[410],{"name":411,"role":69,"phone":412,"phoneExt":62,"email":413},"Luis Paz-Ares Rodríguez, Dr","+34 (91390) 8000","lpazaresr@seom.org",{"facility":415,"status":75,"city":402,"state":402,"zip":416,"country":344,"countryCode":345,"cosmosGeoPoint":417,"geoPoint":419,"contacts":420},"University Hospital HM Sanchinarro","28050",{"type":82,"coordinates":418},[406,407],{"lat":407,"lon":406},[421],{"name":422,"role":69,"phone":423,"phoneExt":62,"email":424},"Gema Garcia Ledo, Dr","+34 (91) 756 7984","gmgarcialedo@hmhospitales.com",{"facility":426,"status":75,"city":427,"state":62,"zip":428,"country":344,"countryCode":345,"cosmosGeoPoint":429,"geoPoint":433,"contacts":434},"University Hospital Lucus Augusti (HULA)","Lugo","27003",{"type":82,"coordinates":430},[431,432],-7.55602,43.00992,{"lat":432,"lon":431},[435],{"name":436,"role":69,"phone":437,"phoneExt":62,"email":438},"Sergio Vázquez Estévez, Dr","+34 (98) 229 6028","sergio.vazquez.estevez@sergas.es",{"facility":440,"status":75,"city":441,"state":62,"zip":442,"country":443,"countryCode":444,"cosmosGeoPoint":445,"geoPoint":449,"contacts":450},"University Hospital Basel","Basel","4031","Switzerland","CH",{"type":82,"coordinates":446},[447,448],7.57327,47.55839,{"lat":448,"lon":447},[451],{"name":452,"role":69,"phone":453,"phoneExt":62,"email":454},"Benjamin Thiele, Dr","+41 (612) 655 074","Benjamin.Thiele@usb.ch",{"facility":456,"status":75,"city":457,"state":62,"zip":458,"country":443,"countryCode":444,"cosmosGeoPoint":459,"geoPoint":463,"contacts":464},"Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology","Sankt Gallen","CH-9007",{"type":82,"coordinates":460},[461,462],9.37477,47.42391,{"lat":462,"lon":461},[465],{"name":466,"role":69,"phone":467,"phoneExt":62,"email":468},"Markus Joerger, Dr","+41 (71) 494 1111","markus.joerger@h-och.ch",{"type":470,"investigatorFullName":62,"investigatorTitle":62,"investigatorAffiliation":62,"oldNameTitle":62,"oldOrganization":62},"SPONSOR","100611921","phase-2-trial-investigating-visugromab-and-nivolumab-with-or-without-docetaxel-in-2l-treatment-of-participants-with-metastatic-nsclc-100611921",false,"NCT07246863","Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)","Main Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed diagnosis of stage IV non-squamous NSCLC.\n* Participants must have demonstrated absence of actionable mutations (e.g. EGFR, ALK, among others) that suggest\u002Frequire treatment with available targeted agent.\n* Participants must have failed one line of prior systemic treatment for metastatic NSCLC containing an approved anti PD (L)1 checkpoint inhibitor (CPI). The minimum treatment duration on this regimen must have been 12 weeks exposure for the CPI with no documented progression in this period. Failure of the prior line of systemic treatment for metastatic NSCLC must have occurred under ongoing CPI treatment. Discontinuation of the prior CPI and line of treatment due to AEs, or any other reason than progression\u002Frelapse does not permit enrollment.\n* Participants must have measurable disease determined by the local site Investigator by their assessment per RECIST v1.1.\n* Participants must have life expectancy of at least 3 months as assessed by the Investigator.\n* Participants must have ECOG performance status ≤1.\n\nMain Exclusion Criteria:\n\n* Participants must not have received more than one line of prior systemic treatment for advanced\u002Fmetastatic NSCLC.\n* Participants must not have a prior malignancy requiring treatment.\n* Participants must not have a known or detected clinically active central nervous system (CNS) involvement by NSCLC or other tumors, e.g., with symptomatic metastases and\u002For carcinomatous meningitis\n* Participants must not have any active autoimmune disease that has required systemic treatment in past 3 months before planned treatment start (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).\n* Participants must not have interstitial lung disease or a history of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis.","ALL","18 Years",{"count":481,"type":482},131,"ESTIMATED","INTERVENTIONAL",[485],"PHASE2","This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor).\n\nThe trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).",[488,489],"Metastatic Non-Squamous Non-Small Cell Lung Cancer","Adult Solid Tumor",[38,491,492],"Visugromab","GDF-15","2026-06-08",{"date":495,"type":496},"2026-06-09","ACTUAL",{"date":498,"type":496},"2025-10-07",{"date":500,"type":482},"2031-10-01",{"name":5,"class":6},25]